Pilot study of peripheral blood chemokines as biomarkers for atrial fibrillation-related thromboembolism and bleeding in elderly patients.
Aged
Aged, 80 and over
Atrial Fibrillation
/ complications
Biomarkers
Chemokine CX3CL1
Chemokine CXCL6
E-Selectin
Hemorrhage
/ epidemiology
Humans
Interleukin-10
Interleukin-4
Interleukin-6
Ligands
Pilot Projects
Thromboembolism
/ epidemiology
Thrombosis
/ epidemiology
Vascular Cell Adhesion Molecule-1
atrial fibrillation
bleeding
chemokine
elderly
thromboembolism
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
12
2021
accepted:
26
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
The scoring systems currently used to identify the potential for thrombosis and bleeding events in high-risk atrial fibrillation patients have certain limitations. The aim of this pilot study was to identify inflammatory chemokines with potential utility as sensitive biomarkers for the risk of thrombosis and bleeding in elderly patients with non-valvular atrial fibrillation. From January 1, 2014, to December 31, 2017, 200 consecutive elderly patients with atrial fibrillation (average age: 87.6 ± 7.7 years) were enrolled and followed up for 2 years to observe thromboembolic (arterial and venous) and bleeding events. Serum was collected upon enrollment, and the baseline levels of 27 chemokines were analyzed. During the 2-year follow-up, 12 patients were lost to follow-up. Among the 188 patients, there were 32 cases (17.0%) of AF-related thrombosis, 36 cases (19.1%) of arterial thrombosis, and 35 cases (18.6%) of major bleeding events. Among 188 patients, 30 patients without clinical events (control group), 23 with arterial thrombosis, 15 with atrial fibrillation-related venous thromboembolism, and 12 with major bleeding were selected and randomly matched to compare chemokine levels. The baseline levels of interleukin-6, interleukin-10, vascular cell adhesion molecule-1, chemokine C-C-motif ligand, B-lymphocyte chemoattractant 1, interleukin-4, E-selectin, fractalkine, C-X-C motif chemokine 12, and granulocyte chemotactic protein 2 were found to differ statistically among the four groups ( Among elderly patients with atrial fibrillation at high risk of thromboembolism and bleeding, the baseline levels of interleukin-6, interleukin-4, and E-selectin were significantly increased in those that experienced thrombosis and bleeding events during the 2-year follow-up, indicating that these chemokines may serve as potential biomarkers for an increased risk of thrombosis and bleeding in this population. ChiCTR-OCH-13003479.
Sections du résumé
Background
The scoring systems currently used to identify the potential for thrombosis and bleeding events in high-risk atrial fibrillation patients have certain limitations. The aim of this pilot study was to identify inflammatory chemokines with potential utility as sensitive biomarkers for the risk of thrombosis and bleeding in elderly patients with non-valvular atrial fibrillation.
Methods
From January 1, 2014, to December 31, 2017, 200 consecutive elderly patients with atrial fibrillation (average age: 87.6 ± 7.7 years) were enrolled and followed up for 2 years to observe thromboembolic (arterial and venous) and bleeding events. Serum was collected upon enrollment, and the baseline levels of 27 chemokines were analyzed. During the 2-year follow-up, 12 patients were lost to follow-up. Among the 188 patients, there were 32 cases (17.0%) of AF-related thrombosis, 36 cases (19.1%) of arterial thrombosis, and 35 cases (18.6%) of major bleeding events.
Results
Among 188 patients, 30 patients without clinical events (control group), 23 with arterial thrombosis, 15 with atrial fibrillation-related venous thromboembolism, and 12 with major bleeding were selected and randomly matched to compare chemokine levels. The baseline levels of interleukin-6, interleukin-10, vascular cell adhesion molecule-1, chemokine C-C-motif ligand, B-lymphocyte chemoattractant 1, interleukin-4, E-selectin, fractalkine, C-X-C motif chemokine 12, and granulocyte chemotactic protein 2 were found to differ statistically among the four groups (
Conclusions
Among elderly patients with atrial fibrillation at high risk of thromboembolism and bleeding, the baseline levels of interleukin-6, interleukin-4, and E-selectin were significantly increased in those that experienced thrombosis and bleeding events during the 2-year follow-up, indicating that these chemokines may serve as potential biomarkers for an increased risk of thrombosis and bleeding in this population.
Clinical trial registration number
ChiCTR-OCH-13003479.
Identifiants
pubmed: 36211709
doi: 10.3389/fpubh.2022.844087
pmc: PMC9538109
doi:
Substances chimiques
Biomarkers
0
Chemokine CX3CL1
0
Chemokine CXCL6
0
E-Selectin
0
Interleukin-6
0
Ligands
0
Vascular Cell Adhesion Molecule-1
0
Interleukin-10
130068-27-8
Interleukin-4
207137-56-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
844087Informations de copyright
Copyright © 2022 Tai, Shi, Wang, Ma, Gao, Chang, Li, Zeng, Shi and Guo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am Heart J. 2004 Sep;148(3):462-6
pubmed: 15389233
Stroke. 2017 Jun;48(6):1524-1530
pubmed: 28455320
Cardiovasc Revasc Med. 2017 Sep;18(6):425-430
pubmed: 28363682
Int J Cardiol Heart Vasc. 2021 Nov 18;37:100918
pubmed: 34849391
Eur J Clin Invest. 2013 Oct;43(10):1032-8
pubmed: 23961715
Rev Port Cardiol (Engl Ed). 2020 Dec;39(12):723-728
pubmed: 33234354
Clin Exp Immunol. 2019 Mar;195(3):310-321
pubmed: 30430560
Chest. 2008 May;133(5):1203-8
pubmed: 18339785
Biochem Soc Trans. 2021 Nov 1;49(5):2371-2380
pubmed: 34581755
Hum Mol Genet. 2004 Feb 15;13(4):389-96
pubmed: 14681304
Heart Rhythm. 2018 Nov;15(11):1717-1727
pubmed: 29908372
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Int J Cardiol. 2013 Oct 25;169(1):62-72
pubmed: 24095158
Hum Immunol. 2014 Mar;75(3):203-7
pubmed: 24374045
Chest. 2015 Jan;147(1):109-119
pubmed: 24921459
Circ Res. 2014 Apr 25;114(9):1453-68
pubmed: 24763464
Eur Heart J. 2003 Jul;24(14):1373-80
pubmed: 12871695
Am J Cardiol. 2017 Oct 1;120(7):1139-1145
pubmed: 28800833
Am J Cardiol. 2012 May 15;109(10):1526-33
pubmed: 22360819
Am J Cardiol. 2007 Jun 1;99(11):1544-8
pubmed: 17531578
J Am Coll Cardiol. 2004 Jun 2;43(11):2075-82
pubmed: 15172416
Int J Cardiol. 2013 Sep 30;168(2):904-9
pubmed: 23167998
Heart Rhythm. 2012 Feb;9(2):189-96
pubmed: 21920484
Curr Pharm Des. 2012;18(28):4289-310
pubmed: 22390641
Blood Coagul Fibrinolysis. 1998 Jun;9(4):297-306
pubmed: 9690800
Clin Sci (Lond). 2009 May;116(10):781-9
pubmed: 18980576
Riv Biol. 2009 Jan-Apr;102(1):61-74
pubmed: 19718623
Curr Med Chem. 2019;26(5):898-908
pubmed: 29022500
Chest. 2007 Oct;132(4):1253-8
pubmed: 17890461
J Leukoc Biol. 2007 Aug;82(2):226-36
pubmed: 17329566
Med Sci Monit Basic Res. 2017 Mar 31;23:97-140
pubmed: 28360407
JAMA Cardiol. 2017 May 1;2(5):516-523
pubmed: 28355442
Int J Cardiol. 2020 Dec 1;320:83-89
pubmed: 32603741
Stroke. 2017 Sep;48(9):2419-2425
pubmed: 28716979
Inflamm Res. 2010 Nov;59(11):965-9
pubmed: 20490891
Circ Res. 2017 Apr 28;120(9):1501-1517
pubmed: 28450367
Am J Cardiol. 2017 Jun 1;119(11):1763-1769
pubmed: 28416199
Eur J Intern Med. 2017 Jun;41:18-27
pubmed: 28343849
Chest. 2015 Jul;148(1):62-72
pubmed: 25501045
Curr Pharm Des. 2012;18(11):1478-93
pubmed: 22364132
Atherosclerosis. 2021 Aug;330:95-106
pubmed: 34247863
Am Heart J. 2015 Dec;170(6):1151-60
pubmed: 26678637
Stroke. 2012 Jan;43(1):86-91
pubmed: 22020034
J Immunol. 2000 Feb 15;164(4):2131-41
pubmed: 10657667
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
Kardiologiia. 2021 Jul 31;61(7):44-54
pubmed: 34397341
Thromb Res. 2011 Dec;128(6):e113-8
pubmed: 21824645
Int J Clin Exp Med. 2014 Nov 15;7(11):4199-206
pubmed: 25550931
Mol Cell Biochem. 2021 Jun;476(6):2283-2293
pubmed: 33575876
Stroke. 2003 Feb;34(2):413-7
pubmed: 12574552
Am J Cardiol. 2005 Mar 15;95(6):764-7
pubmed: 15757607